South Asian consensus guideline: Use of GLP-1 receptor agonists during Ramadan: Update 2016 Revised Guidelines on the use of GLP-1A in Ramadan

J Pak Med Assoc. 2016 Jun;66(6):774-6.

Abstract

This guidance is an update to the South Asian Consensus Guideline: Use of GLP1RA in Diabetes during Ramadan, published in the Indian Journal of Endocrinology and Metabolism in 2012. A five country working group has collated evidence and experience to suggest guidelines for the safe and rational use of glucagon-like peptide1 receptor agonists during Ramadan. The suggestions contained herewith are based upon recently published evidence as well as available basic pharmacological data.

Keywords: Dulaglutide, Exenatide QW, GLP1RA, Hypoglycaemia, Liraglutide, Lixisenatide, Ramadan, South Asia..

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Fasting
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Islam*
  • Liraglutide
  • Peptide Fragments / therapeutic use*
  • Peptides
  • Practice Guidelines as Topic
  • Venoms

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Peptide Fragments
  • Peptides
  • Venoms
  • glucagon-like peptide 1 (7-36)amide
  • Liraglutide
  • Glucagon-Like Peptide 1